ArticleNPJ breast cancer2026

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.

Joyce O'Shaughnessy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.